Overview

Genetic Expression in Schizophrenics Treated With SSRI Augmentation: Relationship to Clinical and Cognitive Function

Status:
Unknown status

Trial end date:
2009-04-01

Target enrollment:

Participant gender:

Summary

In our study we aim to examine the effect of SSRI augmentation on negative symptoms and cognitive function in schizophrenia patients as well as to examine the effect of SSRI augmentation on the RNA and protein products in peripheral mononuclear cells (PMC). Finally, we aim to relate changes in PMC elements to changes in clinical symptoms and cognitive function. Our study hypotheses are that SSRI augmentation of anti-psychotic treatment in schizophrenia patients will improve negative symptoms as well as cognitive symptoms and that this improvement will be related to biochemical changes identifiable in PMC elements.

Phase:

N/A

Details

Lead Sponsor:

Sha'ar Menashe Mental Health Center
Sha’ar Menashe Mental Health Center

Treatments:

Fluvoxamine